Abken, 2015 - Google Patents
Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumorsAbken, 2015
- Document ID
- 5585299708027124043
- Author
- Abken H
- Publication year
- Publication venue
- Immunotherapy
External Links
Snippet
Recent spectacular success in the adoptive cell therapy of leukemia and lymphoma with chimeric antigen receptor (CAR)-modified T cells raised the expectations that this therapy may be efficacious in a wide range of cancer entities. The expectations are based on the …
- 210000001744 T-Lymphocytes 0 title abstract description 231
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abken | Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors | |
| Labanieh et al. | CAR immune cells: design principles, resistance and the next generation | |
| Morgan et al. | Use of cell and genome modification technologies to generate improved “off-the-shelf” CAR T and CAR NK cells | |
| Zhao et al. | Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons | |
| Watanabe et al. | Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology | |
| Guedan et al. | Emerging cellular therapies for cancer | |
| Basar et al. | Next-generation cell therapies: the emerging role of CAR-NK cells | |
| Weber et al. | The emerging landscape of immune cell therapies | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Koury et al. | Immunotherapies: exploiting the immune system for cancer treatment | |
| Lee et al. | The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer | |
| Gilham et al. | CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe | |
| Maus et al. | Chimeric antigen receptor T-cell therapy for the community oncologist | |
| Cheadle et al. | CAR T cells: driving the road from the laboratory to the clinic | |
| Maus et al. | Antibody-modified T cells: CARs take the front seat for hematologic malignancies | |
| Jensen et al. | Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Almåsbak et al. | CAR T cell therapy: a game changer in cancer treatment | |
| Kalaitsidou et al. | CAR T-cell therapy: toxicity and the relevance of preclinical models | |
| Ramos et al. | Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy | |
| Tasian et al. | CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL) | |
| Barrett et al. | Chimeric antigen receptor–and TCR-modified T cells enter main street and wall street | |
| Firor et al. | From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy | |
| Figueroa et al. | Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy | |
| Escobar et al. | Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens |